WO2006058720A3 - Nouveaux composes pour le traitement de troubles neurologiques - Google Patents

Nouveaux composes pour le traitement de troubles neurologiques Download PDF

Info

Publication number
WO2006058720A3
WO2006058720A3 PCT/EP2005/012765 EP2005012765W WO2006058720A3 WO 2006058720 A3 WO2006058720 A3 WO 2006058720A3 EP 2005012765 W EP2005012765 W EP 2005012765W WO 2006058720 A3 WO2006058720 A3 WO 2006058720A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
novel compounds
neurological disorders
disease
compounds
Prior art date
Application number
PCT/EP2005/012765
Other languages
English (en)
Other versions
WO2006058720A2 (fr
Inventor
Andre Johannes Niestroj
Ulrich Heiser
Ingo Schulz
Jens-Ulrich Rahfeld
Joachim Baer
Hans-Ulrich Demuth
Original Assignee
Probiodrug Ag
Andre Johannes Niestroj
Ulrich Heiser
Ingo Schulz
Jens-Ulrich Rahfeld
Joachim Baer
Hans-Ulrich Demuth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/976,677 external-priority patent/US20050137142A1/en
Priority claimed from US11/002,169 external-priority patent/US20050171112A1/en
Application filed by Probiodrug Ag, Andre Johannes Niestroj, Ulrich Heiser, Ingo Schulz, Jens-Ulrich Rahfeld, Joachim Baer, Hans-Ulrich Demuth filed Critical Probiodrug Ag
Priority to EP05826439A priority Critical patent/EP1824846A2/fr
Priority to JP2007543765A priority patent/JP2008521853A/ja
Publication of WO2006058720A2 publication Critical patent/WO2006058720A2/fr
Publication of WO2006058720A3 publication Critical patent/WO2006058720A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux inhibiteurs de propyl endopeptidase de formule (I), soit W-KCONH-X-CON-Y-CO-Z, dans laquelle K, W, X, Y et Z sont tels que définis dans la description. Ces composés sont utiles pour le traitement de maladies telles que la déficience cognitive bénigne (MCI), la maladie d'Alzheimer, le syndrome de Down, la maladie de Parkinson et la chorée de Huntington.
PCT/EP2005/012765 2003-11-03 2005-11-30 Nouveaux composes pour le traitement de troubles neurologiques WO2006058720A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05826439A EP1824846A2 (fr) 2003-11-03 2005-11-30 Nouveaux composes pour le traitement de troubles neurologiques
JP2007543765A JP2008521853A (ja) 2004-12-02 2005-11-30 神経疾患治療用の新規化合物

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US51671703P 2003-11-03 2003-11-03
US10/976,677 US20050137142A1 (en) 2003-11-03 2004-10-29 Combinations useful for the treatment of neuronal disorders
US11/002,169 US20050171112A1 (en) 2003-11-03 2004-12-02 Combinations useful for the treatment of neuronal disorders
US11/002,169 2004-12-02
US68413705P 2005-05-24 2005-05-24
US60/684,137 2005-05-24

Publications (2)

Publication Number Publication Date
WO2006058720A2 WO2006058720A2 (fr) 2006-06-08
WO2006058720A3 true WO2006058720A3 (fr) 2006-07-27

Family

ID=38331139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/012765 WO2006058720A2 (fr) 2003-11-03 2005-11-30 Nouveaux composes pour le traitement de troubles neurologiques

Country Status (2)

Country Link
EP (1) EP1824846A2 (fr)
WO (1) WO2006058720A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
EP2091948B1 (fr) 2006-11-30 2012-04-18 Probiodrug AG Nouveaux inhibiteurs de glutaminylcyclase
MX2009009234A (es) 2007-03-01 2009-12-01 Probiodrug Ag Uso nuevo de inhibidores de ciclasa de glutaminilo.
EP2865670B1 (fr) 2007-04-18 2017-01-11 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (fr) 2010-04-21 2016-01-06 Probiodrug AG Inhibiteurs de glutaminyl cyclase
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154353A2 (fr) * 1984-03-09 1985-09-11 Kabushiki Kaisha Yakult Honsha Agent antiamnésique
EP0201741A2 (fr) * 1985-04-16 1986-11-20 Suntory Limited Dérivés de dipeptides, procédé de préparation, compositions pharmaceutiques et utilisation
US5547978A (en) * 1993-01-15 1996-08-20 Meiji Seika Kaisha, Ltd. Derivatives of pyrrolidin-2-ylcarbonylheterocyclic compounds
US20050171112A1 (en) * 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
WO2005075436A2 (fr) * 2004-02-05 2005-08-18 Probiodrug Ag Nouveaux inhibiteurs de la glutaminyl-cyclase
WO2005103043A1 (fr) * 2004-04-20 2005-11-03 Merck & Co., Inc. Composes derives de pyridyle substitues aux positions 2, 4, 6 utiles comme inhibiteurs de la beta-secretase dans le traitement de la maladie d'alzheimer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6137764A (ja) 1984-07-31 1986-02-22 Suntory Ltd 抗プロリルエンドペプチダ−ゼ活性を有する新規生理活性化合物
ES2058089T3 (es) 1986-11-20 1994-11-01 Ono Pharmaceutical Co Un procedimiento para la preparacion de un nuevo derivado de prolinal.
CA1339423C (fr) 1988-09-14 1997-09-02 Yuji Ono Pyridines et leur emploi en pharmacie
JP2511605B2 (ja) 1990-06-04 1996-07-03 ファイザー・インコーポレーテッド 芳香性ピロリジンおよびチアゾリヂンアミド類
WO1994012474A1 (fr) 1992-11-20 1994-06-09 Japan Tobacco Inc. Compose inhibant la prolyle endopeptidase et utilisation pharmaceutique de ce dernier
WO1995003277A1 (fr) 1993-07-23 1995-02-02 Zaidan Hojin Biseibutsu Kagaku Kenkyukai Nouveau derive de pyrrolidine
ATE223894T1 (de) 1993-12-02 2002-09-15 Merrell Pharma Inc Prolyl-endopeptidaseinhibitoren
HUT76640A (en) 1995-08-17 1997-10-28 Chinoin Gyogyszer Es Vegyeszet Compounds of pharmaceutical activity cyclic amide derivatives, pharmaceutical compositions containing them, process for producing them and their use
US5763576A (en) 1995-10-06 1998-06-09 Georgia Tech Research Corp. Tetrapeptide α-ketoamides
HUP9700442A1 (hu) 1997-02-14 1999-09-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Gyűrűs amidszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
ATE439351T1 (de) 1998-06-24 2009-08-15 Aventis Pharma Inc Fluorphenyl-harzverbindungen
EP1105412A1 (fr) 1998-08-17 2001-06-13 Cortech, Inc. Inhibiteurs de serine protease contenant des alpha-ceto heterocycles

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154353A2 (fr) * 1984-03-09 1985-09-11 Kabushiki Kaisha Yakult Honsha Agent antiamnésique
EP0201741A2 (fr) * 1985-04-16 1986-11-20 Suntory Limited Dérivés de dipeptides, procédé de préparation, compositions pharmaceutiques et utilisation
US5547978A (en) * 1993-01-15 1996-08-20 Meiji Seika Kaisha, Ltd. Derivatives of pyrrolidin-2-ylcarbonylheterocyclic compounds
US20050171112A1 (en) * 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
WO2005075436A2 (fr) * 2004-02-05 2005-08-18 Probiodrug Ag Nouveaux inhibiteurs de la glutaminyl-cyclase
WO2005103043A1 (fr) * 2004-04-20 2005-11-03 Merck & Co., Inc. Composes derives de pyridyle substitues aux positions 2, 4, 6 utiles comme inhibiteurs de la beta-secretase dans le traitement de la maladie d'alzheimer

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM. LETT., vol. 10, no. 1, 2000, pages 45 - 48 *
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 22, 15 November 2004 (2004-11-15), pages 5579 - 5583, XP004598598 *
BR. J. PHARMACOL., vol. 117, no. 5, 1996, pages 986 - 992 *
DATABASE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt/Main, DE; XP002378930 *
DATABASE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt/Main, DE; XP002378931 *
DATABASE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt/Main, DE; XP002378932 *
DATABASE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt/Main, DE; XP002378933 *
DATABASE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt/Main, DE; XP002378934 *
DATABASE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt/Main, DE; XP002378935 *
DATABASE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt/Main, DE; XP002378936 *
DATABASE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt/Main, DE; XP002378937 *
DATABASE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt/Main, DE; XP002378938 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FERRARIS, D. ET AL.: "Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors", XP002378939, retrieved from STN Database accession no. 2004:863108 *
DE NANTEUIL, G. ET AL.: "Prolyl endopeptidase inhibitors: a new class of memory enhancing drugs", DRUGS OF THE FUTURE, vol. 23, no. 2, 1998, pages 167 - 179, XP002124435 *
J. CHEM. SOC. PERKIN TRANS. 2, vol. 1, 2001, pages 113 - 120 *
JOYEAU, R. ET AL.: "Synthesis and activity of pyrrolidinyl- and thiazolidinyl-dipeptide derivatives as inhibitors of the Tc80 prolyl oligopeptidase from Trypanosoma cruzi", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 35, no. 2, February 2000 (2000-02-01), pages 257 - 266, XP004330419, ISSN: 0223-5234 *
JUSTUS LIEBIGS ANN. CHEM., vol. 642, 1961, pages 133 - 140 *
SYNTHESIS, no. 11, August 2004 (2004-08-01), pages 1806 - 1813 *
SYNTHESIS, no. 16, November 2004 (2004-11-01), pages 2645 - 2652 *
TETRAHEDRON LETT., vol. 34, no. 2, 1993, pages 211 - 214 *
TETRAHEDRON LETT., vol. 35, no. 4, 1994, pages 591 - 594 *
TETRAHEDRON, vol. 55, 1999, pages 15001 - 15010 *
TSUTSUMI, S. ET AL.: "alpha-Ketothiazole Inhibitors of Prolyl Endopeptidase", BIOORG. MED. CHEM. LETT., vol. 4, no. 6, 1994, pages 831 - 834, XP004229391 *
TSUTSUMI, S. ET AL.: "Prolyl Endopeptidase Inhibitors. II. A Peptidyl alpha-Keto Thiazole Derivative", ACTA CRYST., vol. C51, 1995, pages 1925 - 1927, XP009065454 *
TSUTSUMI, S. ET AL.: "Synthesis and Sructure-Activity Relationships of Peptidyl alpha-Keto Heterocycles as Novel Inhibitors of Prolyl Endopeptidase", J. MED. CHEM., vol. 37, no. 21, 1994, pages 3492 - 3502, XP002067396 *

Also Published As

Publication number Publication date
EP1824846A2 (fr) 2007-08-29
WO2006058720A2 (fr) 2006-06-08

Similar Documents

Publication Publication Date Title
WO2006058720A3 (fr) Nouveaux composes pour le traitement de troubles neurologiques
WO2004078144A3 (fr) Composes diphenylethylene et leurs utilisations
WO2004014322A3 (fr) Compositions immunomodulatrices, leurs methodes de preparation et utilisation
WO2005046603A3 (fr) Composes pyridiniques
WO2005086656A3 (fr) Derives d'heteroarylaminopyrazole utilises pour traiter le diabete
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
WO2007079199A3 (fr) Inhibiteurs de métalloprotéases à base de bisamides substitués
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
WO2006085149A3 (fr) Methodes et compositions de traitement de maladies liees a l'amyloide
MY142988A (en) Novel aminobenzophenone compounds
WO2007120647A3 (fr) Compositions utiles en tant qu'inhibiteurs de canaux sodiques sensibles a la tension
WO2005033099A3 (fr) Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant
WO2006078576A3 (fr) Inhibiteurs de la $g(b)-secretase d'aminomethyle dans le traitement de la maladie d'alzheimer
WO2006028963A3 (fr) Composes heterocycliques substitues et leurs utilisations
WO2006018188A3 (fr) Hydantoines substituees
WO2006026747A3 (fr) Composes de diphenylethylene et leurs utilisations
WO2006055434A3 (fr) Inhibiteurs de la beta-secretase formes d'amines tertiaires macrocycliques pour le traitement de la maladie d'alzheimer
WO2006057945A3 (fr) Derives pyridyle 2,3,4,6-substitues utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2006042103A3 (fr) Inhibiteurs reversibles de la cathepsine b
WO2007017511A3 (fr) Composes utilises pour traiter la maladie d'alzheimer
WO2004043379A3 (fr) Composes chimiques
GB0322510D0 (en) Novel compounds
WO2005112923A3 (fr) Dérivés de 5-anilino-4-hétéroarylpyrazole utiles pour le traitement du diabete
WO2004087700A8 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation de la douleur

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007543765

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005826439

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005826439

Country of ref document: EP